株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

オーファンドラッグ (希少疾患治療薬) の世界市場:2017〜2021年

Global Orphan Drugs Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 294950
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.37円で換算しております。
Back to Top
オーファンドラッグ (希少疾患治療薬) の世界市場:2017〜2021年 Global Orphan Drugs Market 2017-2021
出版日: 2017年04月05日 ページ情報: 英文 70 Pages
概要

世界のオーファンドラッグ市場は2014〜2019年にかけCAGR10.20%で拡大すると予測されています。

当レポートでは、世界のオーファンドラッグ市場について調査し、地域別動向、今後の市場成長見込み、2021年の市場規模予測、市場成長の課題、主要ベンダーの動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 規制当局の承認

  • オーファンドラッグに関する法律

第7章 製品別市場セグメンテーション

  • 世界の生物学的オーファンドラッグ市場
  • 世界の非生物学的オーファンドラッグ市場

第8章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第9章 決定機構

第10章 市場促進因子と課題

第11章 市場動向

第12章 競合シナリオ

  • ベンダー環境

第13章 主要ベンダー分析

  • AbbVie
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • その他の注目すべきベンダー

第14章 付録

  • 略語一覧

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR11611

About Orphan Drugs

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavio's analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Celgene
  • F. Hoffmann La Roche
  • Novartis

Other Prominent Vendors

  • Amgen
  • Actelion
  • Alexion Pharmaceuticals
  • Bayer
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Johnson & Johnson
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Shire
  • Teva pharmaceutical

Market driver

  • Large growth opportunities through orphan drug designation.
  • For a full, detailed list, view our report

Market challenge

  • Costly treatment regimen results in financial burden on patients.
  • For a full, detailed list, view our report

Market trend

  • Emerging application for orphan drug development.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights
  • Pipeline analysis

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Regulatory approval

  • Orphan drug legislation

PART 07: Market segmentation by product type

  • Biologics
  • Non-biologics

PART 08: Geographical segmentation

  • Orphan drugs market in Americas
  • Orphan drugs market in EMEA
  • Orphan Drugs Market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market Drivers
  • Impact of drivers on key customer segments
  • Market Challenges
  • Impact of challenges on key customer segments

PART 11: Market trends

  • Emerging applications for orphan drug development
  • Increasing focus on development of biologics
  • Repurposing of non-orphan drugs to orphan drugs

PART 12: Competitive Scenario

  • Vendor landscape

PART 13: Key vendor analysis

  • AbbVie
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • Other prominent vendors

PART 14: Appendix

  • List of Abbreviations

List of Exhibits

  • Exhibit 01: Overview of phase III molecules for few vendors
  • Exhibit 02: Pipeline overview based on different therapies
  • Exhibit 03: Pipeline analysis
  • Exhibit 04: Global orphan drugs market snapshot
  • Exhibit 05: Orphan drug requests' year-over-year growth 2014-2016
  • Exhibit 06: Few breakthroughs in global orphan drugs market 2014-2016
  • Exhibit 07: Global orphan drugs market 2016-2021 ($ billions)
  • Exhibit 08: Opportunity analysis in global orphan drugs market
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global orphan drugs market segmentation based on product type
  • Exhibit 11: Increasing trend of approval of biologics
  • Exhibit 12: Global orphan drugs market for biologics 2016-2021 ($ billions)
  • Exhibit 13: Few significant non-biologics approved as orphan drugs
  • Exhibit 14: Global orphan drugs market for non-biologics 2016-2021 ($ billions)
  • Exhibit 15: Global orphan drugs market by geography 2016 and 2021
  • Exhibit 16: Global orphan drugs market by geography 2016-2021 ($ billions)
  • Exhibit 17: Global orphan drugs market share by geography 2016-2021
  • Exhibit 18: Market Scenario in Americas
  • Exhibit 19: Orphan drugs market in Americas 2016-2021 ($ billions)
  • Exhibit 20: Market scenario in EMEA
  • Exhibit 21: Orphan drugs market in EMEA 2016-2021 ($ billions)
  • Exhibit 22: Market scenario in APAC
  • Exhibit 23: Orphan drugs market in APAC 2016-2021 ($ billions)
  • Exhibit 24: Increase in FDA approval of orphan drugs 2012-2015
  • Exhibit 25: List of few benefits through orphan drug designation
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Current pricing scenario of orphan drugs
  • Exhibit 28: Impact of challenges
  • Exhibit 29: Successful examples of repurposed blockbuster orphan drugs
  • Exhibit 30: Competitive structure analysis of global orphan drugs market 2016
  • Exhibit 31: Competitive analysis of global orphan drugs market
  • Exhibit 32: AbbVie: Key highlights
  • Exhibit 33: AbbVie: Key orphan drugs
  • Exhibit 34: AbbVie: Strength assessment
  • Exhibit 35: AbbVie: Strategy assessment
  • Exhibit 36: AbbVie: Opportunity assessment
  • Exhibit 37: Celgene: Key highlights
  • Exhibit 38: Celgene: Key orphan drugs
  • Exhibit 39: Celgene: Strength assessment
  • Exhibit 40: Celgene: Strategy assessment
  • Exhibit 41: Celgene: Opportunity assessment
  • Exhibit 42: Roche: Key highlights
  • Exhibit 43: Roche: Key orphan drugs
  • Exhibit 44: Roche: Strength assessment
  • Exhibit 45: Roche: Strategy assessment
  • Exhibit 46: Roche: Opportunity assessment
  • Exhibit 47: Novartis: Key highlights
  • Exhibit 48: Novartis: Key orphan drugs
  • Exhibit 49: Novartis: Strength assessment
  • Exhibit 50: Novartis: Strategy assessment
  • Exhibit 51: Novartis: Opportunity assessment
Back to Top